Is A2 milk about to leap forward?

Shares in The a2 Milk Company (coded as ATM on the NZX stock exchange) have increased from 48.5 cents on 29 May to 75 cents at 3 July. The market capitalisation has risen from $330 million to $495 million. Where the shares will go in the next few weeks is a journey into the unknown.

What is known is that some of the international big boys have been putting together a syndicate to purchase ATM (also listed jointly on the Australian exchange as A2M). The publicly announced parties are America’s Dean Foods and Australia’s Freedom Foods. But in the background are Australia’s Perich family, Australia’s Moxey family, and China’s New Hope agri-food conglomerate. And hovering nearby is Richard Liu from the rapidly growing Chinese online marketer JD.com.

So far there is no formal buy-out bid, and there could be multiple twists and turns. But this is a team that looks serious!

First of all, I need to declare my own interests. I have been following the A2 saga for more than 10 years and I have written a book on the scientific and political issues ( ‘Devil in the Milk’}. I also write on the topic here at my own website. In 2014, I co-authored two research publications in international science journals, and I remain engaged in the science, working with overseas teams.

Although I have consulted for ATM in relation to the science (last in 2013) and still communicate with them regularly on these matters, I have no special knowledge as to current commercial events. I rely on what is in the public arena. But having been involved in the A2 saga for more than 10 years, I have a background that can be helpful in putting the jigsaw pieces together.

For a long time, I have been confident that all dairy herds will eventually have to be converted to the A2-type. In essence, that means milk that is free from A1 beta-casein, which is the source of the opioid peptide beta-casomorphin -7 (BCM-7). This BCM-7 is a nasty little devil.

This BCM-7 opioid peptide is only released on digestion of A1 cow milk. Goat milk, sheep milk and human milk are all of the A2 type.

So what is the background to this syndicate wanting to buy ATM?

First of all there is Freedom Foods. They are the leading Australian company for foods free of gluten. nuts, and other allergens. Although Freedom Foods is a public company, with market capitalisation on 3 July 2015 of AUD 464 million), the company is effectively controlled by the Perich family which holds the majority of shares. Freedom Foods already holds a 17.8% share in ATM and the Perich family holds another 1.3% in ATM.

The Perichs are a multi-generation business family from Western Sydney with extensive interests in urban property and dairy as well as Freedom Foods. In 2014 they were listed by BRW as having a wealth of AUD $1.02 billion. That may well be conservative. They are major suppliers of A2 milk to ATM.

Dean Foods is America’s largest marketer of fresh milk, with a 35% national market share. Despite its size, Dean Foods has been struggling in recent years and needs some differentiated products. It will have noticed the release of ‘a2 Milk’ in Southern California and will have decided it needs to get a stake in taking the business America-wide.

The Moxeys are currently producers of 50 million litres of milk per annum, which probably makes them Australia’s largest dairy farmers. Most of their milk currently goes to ATM. In recent months they have been re-aligning their business interests in association with the Perich family, Freedom Foods and China’s New Hope. Their new entity called Australian Fresh Milk Holdings (AFMH) was formally announced on 3 July. This will allow a major expansion of dairy operations, with the milk going to Freedom Foods for processing and then for onward sale in China and South East Asia through New Hope.

New Hope is a huge Chinese agri-food conglomerate that has business operations that extend throughout South East Asia. Some years back I visited their headquarters in Chengdu, the capital of China’s Sichuan Province. I gained the impression then that New Hope has no experience in failing and they intend to keep things that way.

JD.com is a burgeoning Chinese online marketer of food and other products with a market capitalisation on Nasdaq of US $46 billion. The owner is Richard Liu whose personal wealth, according to the Sydney Morning Herald is about US $9.4 billion. Liu recently announced his intention to set up a one-stop ‘Australia Mall’ for online selling of Australian foods, including’ a2 Milk. Liu already has business relationships with both New Hope and ATM.

The combination of all of these stakeholders creates huge financial and market power. In essence, it allows ATM to go global. My assumption is that in the process it will de-list from the NZX.

The price which the shares might reach in a takeover is pure speculation. In mid-2014, UBS undertook an analysis of ATM and suggested in a takeover bid the share price could rise to about $1.41. This was based on a company value of NZ $930 million. At the time, the market largely ignored this assessment.

If the bid fails, then a complicating factor is that ATM relies on the Moxey and Perich dairy herds for much of its Australian supply of milk. It is unknown as to the details of their current supply contracts with ATM, and whether the new AFMH entity will be bound by such contracts. Without this milk supply, the Australian arm of ATM is in big trouble.

There is a huge irony in all of this. It was in New Zealand that A2 milk started, yet ATM now has a negligible presence in this country. Unlike Australia, where a2 Milk (i.e. the ATM brand) is the leading supermarket brand of milk, it is only available in a few New Zealand supermarkets and even then only as full cream milk.

Twenty years have passed since Professor Bob Elliott’s initial work at Auckland University showing the relevance of BCM-7. This was then carried forward by scientist-entrepreneur Corran McLachlan and financial mastermind Howard Paterson. If it were not for the tragic deaths of McLachlan and Paterson within weeks of each other back in 2003, then the history of New Zealand’s dairy industry would tell a different story.

I recall a discussion with Fonterra director about seven years ago, when that director bragged to me that Fonterra could ‘take out’ A2 Milk (as it was then titled) whenever they wished. It was, he said, no more than an annoying little flea.

As of 2015, the reality is that Fonterra could no longer purchase ATM even if it so wished. Quite simply, Fonterra does not have the financial wherewithal to join a bidding war.

However, Fonterra does not need to purchase ATM. All along, Fonterra has held a 50% share in one of the crucial patents that would have allowed it to make the shift. That particular patent runs out later this year, but Fonterra could still make the shift thereafter, without legal hindrance.

In 2008, Westland Dairy Co-operative, led by CEO Scott Eglinton, did make made the call to go A2. However, Eglinton was another to suffer a tragic death, and in 2009 under a new CEO the policy was reversed.

The downside when Fonterra, Westland and other New Zealand do eventually make the shift to A2 is that it will be without any of the early mover advantages. And when it does happen, the transition will be much slower than for the big American herds and even the big Chinese herds.

The reason for the slower transition in New Zealand will be that most farmers only have one herd. In contrast, the big overseas production companies have sufficient scale to immediately separate off their A2 animals into A2 herds, and then rapidly transition the remaining herds using female sex-selected A2 semen and high replacement rates. Oh dear!

Advertisements

About Keith Woodford

Keith Woodford is an independent consultant, based in New Zealand, who works internationally on agri-food systems and rural development projects. He holds honorary positions as Professor of Agri-Food Systems at Lincoln University, New Zealand, and as Senior Research Fellow at the Contemporary China Research Centre at Victoria University, Wellington.
This entry was posted in A1 and A2 milk, Agribusiness. Bookmark the permalink.

15 Responses to Is A2 milk about to leap forward?

  1. I’ve been informed that the dairy products at Clandeboyne are nearly entirely A2. Only 2 of their donor bulls are not A2 at this stage. When I read your book, Keith, it was evident to me that Fonterra were stealthily making the transistion to A2 herds while decrying the science. At that stage you wrote that the A2 percentage in the bulls in 2005 was running at 65%. Clandeboyne in South Canterbury collects milk from a hinterland of 250 km radius approximately (excepting the sea of course).

    It’s a shame you’re no longer involved in the A2 corporation as you deserved to be rewarded for your perserverence amid the nastiness of the dairying thugs. However the inconvenience of 3 lead players’ untimely deaths would have encouraged me to exit stage left.

    • Keith Woodford says:

      Hello Honora
      I doubt the accuracy of your informant re Clandeboye. My guess is that the relative frequency of A1 to A2 in the milk collected at Fonterra’s Clandeboye factory will be about 35:65. I make that estimate from a knowledge of the bulls that have been used. I could be wrong by a few percent.
      Keith Woodford

      • Honora Renwick says:

        Oh well, then I have been misinformed. Back to my source! Just out of curiosity, how many bulls would be being used?

        cheers, Honora

      • Keith Woodford says:

        Honora
        I would need to check the LIC and Ambreed catalogues to give an accurate figure. But all in all, probably about 100 bulls are used in the AI program. Of these, about 30 would be used for large numbers of cows.
        Keith

      • Honora Renwick says:

        Oh yeah, it was Synlait who were offering a double premium for A2 milk, supplying A2 milk powder to Australia. And it was just one of the driers that was entirely dedicated to A2. Anyway I got to learn about ‘semen of the day’ half-price specials and other interesting facts!

  2. Louise McConnell says:

    I still keep coming across people who think they are lactose intolerant but in fact are A1 intolerant. I get them some A2 pure milk and suddenly the revelation that they could have drunk milk or lattes after all if they sourced A2 milk. It is very sad that vested interests in NZ have tried to stifle the growth of A2 milk. I rang a local processor to see if they wanted our A2 milk but they were not interested.
    We have been steadily breeding A1 cows out of our herd. We started as soon as we read the work of Bob Elliot et al in 2000 and it has taken 15 years and we have also taken the trouble to breed up A2A2 Red Devon’s as we found that the A1 genetic mutant was prevalent in that breed and there has been Australian research suggesting that there is meat tenderness associated with the A2 gene. (Have you ever noticed how tender a Jersey beef cross bred animal is and the A2 gene is very prevalent in that breed?).
    New Zealand dairy farmers should make every effort to use just A2 bulls and steadily quietly remove A1 cows from the national herd as this issue is a looming ticking time bomb.
    It is so disappointing to see NZ findings are being lost to overseas interests who will take the bit between the teeth and run and make money out of it. New Zealanders have a history of doing this.
    Perhaps the A2 is jinxed in New Zealand and it may improve personal longevity by not being associated with it but the fact that you are still alive Keith gives me hope!!

  3. Pingback: Is A2 milk about to leap forward? | Agrigator

  4. Pingback: Rural round-up | Homepaddock

  5. Anne says:

    Is it possible to find A2 milk in the USA?

    • Keith Woodford says:

      Anne, It seems I missed your question. Currently A2 is available in Southern California, and about to be released in Northern California. It is also becoming available in some health stores across many states. A question to the a2 Milk Company at their website could be worthwhile as the availability is increasing he time.
      Keith

  6. Gina deNicolo says:

    It is my understanding that the EFSA found no link between chronic diseases and consumption of A1 milk. Are there not also studies done that shown no effect? A brief search tells me some of the work attributing A2 to better health (or A1 to diseases) is flawed and/or misinterpreted/misrepresented.

    • Keith Woodford says:

      Gina
      Yes, that is essentially what EFSA found. Note that EFSA really only looked at chronic systemic diseases in humans. They ignored much of the animal evidence and they did not look at digestive effects. Of course the science has moved on a lot since EFSA (which was written in 2008 and published at the start of 2009). Have a look at the A1 and A2 milk category on this website. Actually, I need to write some more posts on A1 and A2, but I have been distracted by other commitments. There was a recent review (2015) in the journal Nutrients authored by Pal, Woodford (that is me), Kukuljan and Ho, focusing on digestive issues. It is free access so you should be able to find the paper by googling all of our surnames. (There are two papers which the four of us have written together; the first was in the European Journal of Clinical Nutrition in 2014 and is reviewed at my website. This more recent paper is not yet reviewed on my website.) There are a number of other papers by various authors in preparation at the moment, and there is also another clinical study about to start. At various times there are claims that the science is mis-represented or flawed, but that seems to come mainly from people with an interest in ensuring ‘ordinary milk’ does not take a hit.
      Keith Woodford

      • Ken Ross says:

        The EFSA Human study trumps any animal (rabbits/mice) study evidence based on obvious biological differences. The actual “Devil” is in the obvious Details that are in plain sight for all to see. You need a lot more than a few statistical correlations and rabbit test subjects.

      • Keith Woodford says:

        Ken, The EFSA study was a review (not a clinical or empirical trial), undertaken in 2008, which focused on systemic issues and did not consider gastro-intestinal effects. It did not produce new evidence. However, the evidence has moved along since then, largely from human-based studies. You do indeed need ‘more than a few statistical correlations and rabbit test subjects’.
        Keith

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s